13
With risk factors on patholog y specimen:
adjuvant RT ± concurrent low-dose
platinum-based chemotherapy aer
hysterectomy
(EB, I, M)
With risk factors on patholog y specimen:
adjuvant RT ± concurrent low-dose
platinum-based chemotherapy aer
hysterectomy
(EB, I, M)
See IB1 See IB1
See IB2 See IB2
d
Margins for dysplasia or carcinoma.
e
Selective lymphadenectomy or LN biopsy for suspicious lesions.
f
Recommended in setting where chemotherapy is not consistently available.
g
Sedlis A et al. Gynecol Oncol. 73:177-183, 1999.
Enhanced Maximal
No. (%)
RT No Additional Therapy
60 (43.0) 68 (48.6)
28 (20.4) 37 (26.4)
48 (35.0) 34 (29.3)
1 (0.7) 1 (0.7)
137 (100.0) 140 (100.0)
